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Since the early 1990s, the role of Chlamydin pncwntoninc in exacer- 
batioiis of asthma has been investigated. In several patients the 
infection is associated with wheezing and asthma onset. Hahn 
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Chlamydiae are obligatory intracellular bacterial pathogens causing a 
variety of acute and chronic diseases in animals and humans. One of 
the major surface antigens of this microorganism is a lipopoly- 
saccharide (LPS) which harbors a genus-specific epitope composed 
of a trisaccharide of 3-deoxy-D-manno-oct-2-ulopyranosonic acid 
(Kdoj of the sequence alpha-Kdo(2-8)-alpha-Kdo-(2-4)-alpha- 
Kdo. This epitope and partial structures thereof have been chemically 
synthesized and converted into artificial neoglycoconjugates, against 
which monoclonal antibodies have been generated. The glycosyl- 
transferase involved in its biosynthesis has been cloned, sequenced, 
expressed and functionally characterized in vitro and in vivo. These 
protcin-carbohydrate interactions have been characterized in detail. 
The results add substantially to our understanding of how carbo- 
hydrates are recognized by proteins, and the advanced knowledge has 
been used to improve the diagnosis of human chlamydial infections, 
by using defined neoglycoconjugates as solid-phase antigens in 
ELISA. This assay allows the sensitive and simple determination of 
LPS antibody levels in patients with chlamydial infections. 
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There are now over 20 seroepidemiologic studies veri$ing the 
association and only two negative reports. The presence of the agent 
in vessel walls has also been demonstrated in over 20 studies, and the 
agent is preferentially found in damaged areas from the age of 15 
onwards. Isolations and RT-PCR have shown it to be active in 
lesions. It is able to multiply in endotheiial cells, macrophages and 
smooth muscle cells, and is a potent inducer of cytokines and 
proteolytic enzymes. In vitro, macrophages infected with Chlamydia 
pneumoniae activate LDL ingestion and are easily transformed to foam 
cells. All these features are also found in inflammation associated with 
atherosclerosis. Moreover, chronic infection caused by this Gram- 
negative intracellular pathogen is associated with elevated levels of 
inflammatory proteins like CRP and fibrinogen, and altered 
metabolism (elevated BMI, elevated cholesterol, blood glucose, and 
lowered HDL levels). In the Helsinki Heart study, the markers of 
chronic C. pnrumoniae infection were the most significant factor in 
the metabolic syndrome. Four laboratories have produced grade I-IV 
arteriosclerotic lesions in experimental animals on normal or 
cholesterol diets, and their development can be prevented with anti- 
biotics. The first two intervention trials with macrolides, although 
quite preliminary, have been successful. The first large-scale inter- 
vention trials have already started and their results will be available in 
about 4 years. Meanwhile, we should develop a diagnostic test for 
detecting patients who would possibly benefit from antibiotic 
treatment before their first cardiac event, and try to find in animal 
experiments the right treatment to eradicate the pathogen. 
reported a dose-response relationship between specific antibody titers 
and wheezing prevalence. Mlegra found that about 10% of asthma 
exacerbations in adults were due to this pathogen. Ernre reported 
similar results in a pediatric population. Moreover, they demonctrated 
that treatment with macrolide iiuy improve the course of reactive 
airway disease. A recent study involving 108 children with asthma 
symptoms, aged 9-1 1 years, showed that chronic C. prierrntoniae 
infection is common in school-age children and immune responsec 
to Chlamydia are positively associated with frequency of asthma 
exacerbations. The authors suggest that the immune recponse to 
chronic C. pneumoniae infection may interact with allergic inflam- 
mation to increase asthma symptoms. Furthermore, thr number of 
episodes reported by each child during the 13 months of the study 
was used to assess the possible relationship between asthma exacrr- 
bations and sIgA to C. pneumoniae. The results of these and other 
studies lead to the hypothesis that C. pneunzoniae chronic infection 
may play a part in the natural history of asthma conditioning, at least 
in the chronic inflammation and hyperresponsivenee$ which 
characterize asthma. A recent study by our group, while confirming 
the role of this pathogen in mild to moderate exacerbations, suggests 
that C. pneumoniae must also be considered as a cause of severe attacks. 
Only large epidemiologic studies and intervention trials will clarify 
the role of the pathogen in the etiopathogenesic of asthma. 
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MS is a chronic inflammatory disease of the central nervous sycteni 
(CNS) in which an infectious agent may be involvcd. We evaluated 
the possible role of C. pnettmoniae in newly diagnosed and progressive 
MS by examining cerebrospinal fluid (CSF) froin over 30 patients 
versus that from over 30 patients with other neurologic diseasec 
(OND). C. pneumoniae was isolated from CSF cultures in 40% of 
newly diagnosed MS patients (7/17) and 80% of progreccivc MS 
patients (lh/20) versus 10% of O N D  controls (3/30). PCK/ 
Southern hybridization assays revealed that the C. pireuwmiiai, 
MOMP gene was present in the CSF of 100% of newly diagnosed 
MS patients (17/17) and 95% of progressive MS patients (19/20) 
versus 17% of O N D  controls (5/30). Over 80% of MS patients had 
increased CSF antibodies to C. pneumoniae elementary body (EB) 
antigens as shown by ELISA absorbance values that were three 
standard deviations greater than those seen in O N D  controk. The 
specificity of these antibodies was evaluated by CSF Western blot 
assays using EB antigens. The results showed multiple reactive bandc 
against C. pneumoniae. CSF isoelectric focusing followed by Western 
blot assays using EB antigens showed the precence of cationic anti- 
bodies against C. pnertmoniae in over 50% of MS patients. These 
observations suggest that CNS infection with C. pneutnoniae is a 
frequent and early occurrence in MS patients and may need to be 
treated with antimicrobial agents. Antimicrobial therapy for chronic 
CNS infections caused by C .  pnerirrioniae raises a number ofimportant 
issues which will be discussed. 
